The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
July 26th 2024
Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.
Trastuzumab Deruxtecan Approved in China for HER2-Low Metastatic Breast Cancer
China’s National Medical Products Administration has approved trastuzumab deruxtecan monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer who have previously received a systemic therapy in the metastatic setting or whose disease recurred during or within 6 months of adjuvant chemotherapy.
Subcutaneous Pertuzumab/Trastuzumab Combo Continues to Prove Safe, Effective in HER2+ Breast Cancer
June 1st 2023Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.
Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer
Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.
FDA Issues Complete Response Letter for Trastuzumab Duocarmazine in Advanced HER2+ Breast Cancer
The FDA has issued a complete response letter to the biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.
Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer
May 11th 2023Patient-reported outcomes with fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial, according to findings presented during the 2023 ESMO Breast Cancer Annual Congress.
Research on Current and Emerging HER2-targeted Agents Continues to Advance Breast Cancer Treatment
April 11th 2023Cynthia X. Ma, MD, PhD, discusses updates in triple-negative breast cancer treatment, recent data on HER2-targeted agents in metastatic and early-stage HER2-positive breast cancer, and the role of CDK4/6 inhibitors and oral selective estrogen receptor degraders in hormone receptor–positive disease.
Novel Tucatinib-based Regimens Highlight Ongoing Research in HER2+ Breast Cancer
Jennifer M. Matro, MD, discusses the real-world implications and uptake of the HER2CLIMB regimen, other trials investigating tucatinib-based regimens in HER2-positive metastatic breast cancer, and how approaches differ between early-stage and metastatic hormone receptor–positive/HER2-negative breast cancer.
Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases
April 6th 2023Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.
FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer
April 5th 2023The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Integrating New Standards for Metastatic HER2+ Breast Cancer
March 20th 2023The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.